A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinop

Project Details

StatusFinished
Effective start/end date25/08/2125/08/23

Funding

  • IQVIA RDS Pty. Limited: A$185,510.00